Showing results (681-690 of 696) with videos related to

Sort By:
Pageof 70
Spinal Cord|April 28, 2018
Lower extremity outcome measures: considerations for clinical trials in spinal cord injuryMarc Bolliger, Andrew R Blight, Edelle C Field-Fote, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2017
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II TrialsBenjamin M Ellingson, Elizabeth R Gerstner, Marion Smits, et al.
Scientific Reports|January 10, 2026
T-cell biomarkers improve urinary tract infection risk stratification beyond clinical characteristics after acute traumatic spinal cord injuryOliver Schweizerhof, Christian Meisel, Christian Blex, et al.
Neuroimage|July 18, 2013
The current state-of-the-art of spinal cord imaging: applicationsC A Wheeler-Kingshott, P W Stroman, J M Schwab, et al.
The New England Journal of Medicine|September 26, 2015
Cabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaToni K Choueiri, Bernard Escudier, Thomas Powles, et al.
Clinical Pharmacology and Therapeutics|December 28, 2016
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics ConsortiumC H van der Wouden, A Cambon-Thomsen, E Cecchin, et al.
Spinal Cord|December 30, 2017
Considerations and recommendations for selection and utilization of upper extremity clinical outcome assessments in human spinal cord injury trialsLinda A T Jones, Anne Bryden, Tracey L Wheeler, et al.
BMC Neurology|November 12, 2013
The SCIentinel study--prospective multicenter study to define the spinal cord injury-induced immune depression syndrome (SCI-IDS)--study protocol and interim feasibility dataMarcel A Kopp, Claudia Druschel, Christian Meisel, et al.
American Journal of Human Genetics|June 19, 1998
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international studyS L Neuhausen, A K Godwin, R Gershoni-Baruch, et al.
The New England Journal of Medicine|March 3, 2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Mauricio Burotto, et al.
Pageof 70